Get the Stockscreener App
17.10
0.06%
-0.010
After Hours:
17.22
0.12
+0.70%
Sarepta Therapeutics Inc stock is traded at $17.10, with a volume of 4.59M.
It is down -0.06% in the last 24 hours and down -54.52% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$17.11
Open:
$17.24
24h Volume:
4.59M
Relative Volume:
0.99
Market Cap:
$3.84B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-6.3569
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
-9.38%
1M Performance:
-54.52%
6M Performance:
-85.94%
1Y Performance:
-89.18%
1-Day Range:
$16.96
$17.52
1-Week Range:
$16.96
$19.43
52-Week Range:
$16.96
$162.95
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.10 | 3.84B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat
Sarepta Therapeutics (SRPT): Mizuho Lowers Price Target to $40 | SRPT Stock News - GuruFocus
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls - Yahoo Finance
Sarepta (SRPT) Faces Price Target Cut Amid Liver Failure Concerns | SRPT Stock News - GuruFocus
TD Cowen downgrades Sarepta Therapeutics to 'hold' - TradingView
Sarepta stock plunges 42% after second fatal liver failure case - Investing.com
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics - BioSpace
Sarepta (SRPT) Downgraded to Hold with Revised Price Target | SRPT Stock News - GuruFocus
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research… - MarketScreener
Sarepta stock downgraded by TD Cowen on Elevidys approval concerns - Investing.com
Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys - Investing.com
Sarepta Therapeutics (SRPT) Price Target Lowered by Deutsche Ban - GuruFocus
Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Therapeutics price target lowered to $28 on safety concerns - Investing.com
Sarepta Therapeutics price target lowered to $28 on safety concerns By Investing.com - Investing.com UK
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI - StreetInsider
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm | FinancialContent - FinancialContent
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation - simplywall.st
Sarepta Therapeutics (SRPT) Downgraded by Goldman Sachs to Neutral | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Downgraded by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Baird | SRPT Stock News - GuruFocus
From $172 to $20: Sarepta’s Spectacular Fall - Trefis
Sarepta Reports Second Death of Patient Using Its Gene Therapy - MSN
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles By Investing.com - Investing.com South Africa
Lilly adds highest Zepbound doses to DTC offering - statnews.com
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | S - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | SRPT Stock News - GuruFocus
Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more - statnews.com
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles - Investing.com India
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire
SRPT Stock: What’s Happening With Sarepta Therapeutics? - Forbes
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target Amid In - GuruFocus
Sarepta (SRPT) Price Target Slashed, Uncertainty Surrounds Future | SRPT Stock News - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Ami - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Amid Safety Concerns | SRPT Stock News - GuruFocus
This Week’s CGT News: Investigating the Long-Term Safety of Gene Therapy for Hemophilia B - themedicinemaker.com
2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy - MSN
Biotech pauses trial after second patient death linked to gene therapy - The Washington Post
Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - MSN
Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns - GuruFocus
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Elevidys’ second liver death hits Sarepta, sends DMD ripples - BioWorld MedTech
Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death - insights.citeline.com
Sarepta shares crash as second patient dies after receiving its gene therapy - MSN
Health Care Down as Sarepta Slides -- Health Care Roundup - MarketScreener
Second patient death reported with gene therapy for muscular dystrophy - Hazleton Standard Speaker
Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment - Bloomberg
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sarepta Therapeutics Inc Stock (SRPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
| Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
| Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):